BTIG Maintains Buy on Aura Biosciences, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Robert Hazlett maintains a Buy rating on Aura Biosciences and raises the price target from $21 to $24.
October 18, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Robert Hazlett has reaffirmed a Buy rating for Aura Biosciences and increased the price target from $21 to $24, indicating positive sentiment and potential upside.
The increase in price target from $21 to $24 by BTIG suggests a positive outlook for Aura Biosciences, likely leading to a short-term increase in stock price as investors react to the analyst's confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100